• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Cytori Therapeutics

Cytori Therapeutics posts mixed Q2

August 11, 2017 By Sarah Faulkner

Cytori Therapeutics

Shares in Cytori Therapeutics (NSDQ:CYTX) fell today after the biotech missed sales expectations on Wall Street with its second quarter results, but topped EPS estimates. The San Diego, Calif.-based company posted a net loss of -$6 million on sales of $1.5 million for the 3 months ended June 30, for bottom-line growth of 6% on sales […]

Filed Under: Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Regenerative Medicine, Wall Street Beat Tagged With: Cytori Therapeutics

Cytori launches next-gen Celution cell therapy tech

June 1, 2017 By Sarah Faulkner

Cytori Therapeutics

Cytori Therapeutics (NSDQ:CYTX) said today that the next-gen version of its Celution cell therapy device is available for pre-order and that the 1st shipments will start in the 3rd quarter of 2017. The San Diego-based company’s Celution system automates the extraction and concentration of autologous, clinical-grade adipose-derived regenerative cells. The next-gen Celution tech includes new […]

Filed Under: Drug-Device Combinations, Featured, Regenerative Medicine, Wall Street Beat, Wound Care Tagged With: Cytori Therapeutics

Cytori prices $9.5m public offering

April 11, 2017 By Sarah Faulkner

Cytori Therapeutics

Cytori Therapeutics (NSDQ:CYTX) said today that it priced an underwritten public offering of 8.6 million shares of common stock at $1.10 apiece. The company plans to bring in $9.5 million. Cytori granted a 45-day underwriter’s option to purchase up to 15% of additional shares of common stock. The offering is expected to close on April […]

Filed Under: Featured, Funding Roundup, Regenerative Medicine, Wall Street Beat Tagged With: Cytori Therapeutics

Cytori wins FDA nod for cell therapy pilot trial

April 10, 2017 By Sarah Faulkner

Cytori Therapeutics

Cytori Therapeutics (NSDQ:CYTX) said today that the FDA approved an Investigational Device Exemption for a pilot trial of the company’s cell therapy in patients with thermal burn injury. The Relief trial is a part of Cytori’s ongoing R&D efforts under its contract with the U.S. Dept. of Health & Human Services’ Biomedical Advanced Research and […]

Filed Under: Clinical Trials, Featured, Food & Drug Administration (FDA), Regenerative Medicine, Regulatory/Compliance, Wall Street Beat Tagged With: Cytori Therapeutics

Azaya Therapeutics bought by Cytori, nanoparticle program launched

February 16, 2017 By Sarah Faulkner

Cytori launches nanoparticle program after acquiring Azaya Therapeutics

Cytori Therapeutics (NSDQ:CYTX) said yesterday that it completed its acquisition of San Antonio-based Azaya Therapeutics and its nanoparticle cancer drugs. In late January, San Diego-based Cytori said it planned to buy Azaya in a stock deal, offering Azaya shareholders $2 million in CTYX stock. Cytori also said that it paid $2 million upfront for costs associated […]

Filed Under: Featured, Mergers & Acquisitions, Nanoparticles, Wall Street Beat Tagged With: Azaya Therapeutics, Cytori Therapeutics

Cytori buys Azaya’s nanoparticle tech in stock deal

January 20, 2017 By Sarah Faulkner

Cytori buys Azaya's nanoparticle tech in stock deal

Cytori Therapeutics (NSDQ:CYTX) said this week that it bought San Antonio-based Azaya Therapeutics and its nanoparticle cancer drugs in a stock deal. Azaya shareholders will receive $2 million in CTYX stock. San Diego-based Cytori will also pay $2 million upfront for costs associated with Azaya’s new manufacturing facility in San Antonio. Cytori will acquire a […]

Filed Under: Featured, Mergers & Acquisitions, Nanoparticles, Oncology, Wall Street Beat Tagged With: Azaya Therapeutics, Cytori Therapeutics

Cytori touts regenerative cell therapy data

October 24, 2016 By Sarah Faulkner

Cytori Therapeutics

Cytori Therapeutics (NSDQ:CYTX) touted the publication of preclinical safety and efficacy data for its cell therapy treatment for combined radiation and thermal injury. The San Diego-based company said the current healthcare system is ill-prepared to care for large numbers of patients that require simultaneous treatment and that patients with severe burns commonly suffer with prolonged […]

Filed Under: Featured, Preclinical Trials, Regenerative Medicine, Research & Development Tagged With: Cytori Therapeutics

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS